Clinical Trial: NCT03817320
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Therapeutic Advances in Childhood Leukemia Consortium |
| Information Provided By: | Therapeutic Advances in Childhood Leukemia Consortium |
| Last Update Posted: | 2025-06-17 |
Study Overview
Brief Summary
This is a phase 1/2 study of a drug called Ixazomib in combination with cytotoxic chemotherapy consisting of Vincristine, Dexamethasone, Asparaginase, and Doxorubicin (VXLD).
Official Title
A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730
Conditions
ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Intervention / Treatment
- Drug: Ixazomib
- Drug: Vincristine
- Drug: Dexamethasone
- Drug: Asparaginase
- Drug: Doxorubicin
- Drug: Methotrexate (IT)
- Drug: Triple IT (Methotrexate, Hydrocortisone, Cytarabine)
- Drug: Leucovorin
Other Study ID Numbers
- T2017-002
Start Date (Actual)
2019-02-12
Primary Completion Date (Actual)
2023-12-03
Study Completion Date (Estimated)
2025-06-30
Enrollment (Actual)
24
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | Therapeutic Advances in Childhood Leukemia Consortium |
| Information Provided By: | Therapeutic Advances in Childhood Leukemia Consortium |
| Last Update Posted: | 2025-06-17 |
Study Overview
Brief Summary
This is a phase 1/2 study of a drug called Ixazomib in combination with cytotoxic chemotherapy consisting of Vincristine, Dexamethasone, Asparaginase, and Doxorubicin (VXLD).
Official Title
A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730
Conditions
ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Intervention / Treatment
- Drug: Ixazomib
- Drug: Vincristine
- Drug: Dexamethasone
- Drug: Asparaginase
- Drug: Doxorubicin
- Drug: Methotrexate (IT)
- Drug: Triple IT (Methotrexate, Hydrocortisone, Cytarabine)
- Drug: Leucovorin
Other Study ID Numbers
- T2017-002
Start Date (Actual)
2019-02-12
Primary Completion Date (Actual)
2023-12-03
Study Completion Date (Estimated)
2025-06-30
Enrollment (Actual)
24
Study Type
Interventional
Phase
Phase 1, Phase 2